---
title: "Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4"
id: "endocrine-news-0-pharma-friday-september-4-2026"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/pharma-friday-september-4-2026/"
published_at: "2026-09-04T16:57:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/pharma-friday-september-4-2026/)
- **Published At:** 2026-09-04T16:57:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This Pharma Friday roundup reports two major FDA actions announced in late August 2026: approval of **Rasonque (daraxonrasib)** for previously treated metastatic pancreatic adenocarcinoma, and approval of **Mounjaro (tirzepatide)** to reduce major adverse cardiovascular events in adults with type 2 diabetes at high CV risk. - Rasonque is a once-daily oral **RAS inhibitor** targeting multiple RAS forms; the approval covers adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or cannot receive multiagent systemic therapy. - In a randomized, open-label multicenter trial of 500 adults with previously treated metastatic pancreatic adenocarcinoma, Rasonque improved median overall survival to 13.2 months versus 6.7 months with standard chemotherapy, per the source. - The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, Priority Review, and reviewed the application under the Commissioner’s National Priority Voucher pilot program; an expanded access protocol had been permitted earlier in May. - Reported common adverse events for Rasonque include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. - On August 28, Eli Lilly announced FDA approval of Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist, to lower the risk of MACE (CV death, nonfatal MI, nonfatal stroke) in adults with type 2 diabetes at high CV risk. - The approval was based on SURPASS-CVOT, the first head-to-head cardiovascular outcomes trial comparing two incretin medicines and the largest tirzepatide study to date, enrolling more than 13,000 participants over 4.5+ years across 30 countries. - In SURPASS-CVOT, Mounjaro demonstrated non-inferiority to **Trulicity (dulaglutide)** with an estimated hazard ratio for time to first MACE of 0.92 (95.3% CI: 0.83, 1.01) and an 8% lower rate of MACE-3 versus dulaglutide. - Safety and tolerability of Mounjaro in the trial were consistent with its established profile; most common adverse events were gastrointestinal, generally mild-to-moderate and occurring during dose escalation. - The roundup quotes FDA and company leaders emphasizing the significance: Rasonque fills a major unmet need in metastatic pancreatic adenocarcinoma and the Mounjaro approval addresses cardiovascular risk in type 2 diabetes while building on its glucose- and weight-related benefits.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/pharma-friday-september-4-2026/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/august-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/pharma-friday-september-4-2026/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Pharma Friday – September 4, 2026 September 4, 2026 Print this article Share this article #### An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * ## FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer On August 26, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. Rasonque, a tablet taken once daily, targets multiple forms of a protein called RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma, which arises from cells lining the ducts of the pancreas. “Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” said Acting FDA Commissioner Kyle Diamantas, J.D. “I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality.” The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Approximately 90% to 95% of the 67,000 new cases of pancreatic cancer diagnosed in the United States each year are pancreatic adenocarcinoma, according to the National Cancer Institute. Despite representing roughly 3.2% of all cancer diagnoses, pancreatic adenocarcinoma accounts for a disproportionately high share of cancer deaths, owing to its typically late detection, aggressive disease course, and historically limited treatment options. In a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma, Rasonque improved median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy. “This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions.” The FDA granted Rasonque [Breakthrough Therapy](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy) and [Orphan Drug](https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products) designations. Rasonque received [Priority Review](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review) for this indication. The application was also reviewed under the [Commissioner’s National Priority Voucher pilot program](https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program), which is intended to help accelerate the review of therapies that address national public health priorities. In May, the FDA [issued](https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug) a “safe to proceed” letter allowing the sponsor to initiate an expanded access treatment protocol for Rasonque, enabling patient access to the investigational drug prior to approval under applicable FDA regulations. The most common side effects of the drug are rash, diarrhea, stomatitis (inflammation of the mouth’s mucus membranes), nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. The FDA granted the approval to **[Revolution Medicines, Inc.](https://www.revmed.com/)** ## FDA approves Lilly’s Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes On August 28, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. > “Heart health deserves attention throughout the course of treatment, not just after a serious cardiovascular event. While a large portion of type 2 diabetes care is focused on glucose control, mitigating cardiovascular risk is essential and can be overlooked.” > **David A. D’Alessio, MD** , study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine “For people with type 2 diabetes, heart disease is the leading cause of death, and Mounjaro … now gives them a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight,” said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health. “We set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit, one that reflects the depth of evidence Lilly continues to build in this field.” ![](https://endocrinenews.endocrine.org/wp-content/uploads/eli_lilly_and_company_logo.jpg) The approval was based on results from SURPASS-CVOT, the first cardiovascular outcomes trial comparing two incretin medicines head-to-head rather than against a placebo, and the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). “Heart health deserves attention throughout the course of treatment, not just after a serious cardiovascular event,” said Endocrine Society member **David A. D’Alessio, MD** , study co-author and director of the Division of Endocrinology and Metabolism at Duke University School of Medicine. “While a large portion of type 2 diabetes care is focused on glucose control, mitigating cardiovascular risk is essential and can be overlooked. This approval gives patients a medicine that reduces the risk of cardiovascular events and supports metabolic health at the same time.” The safety and tolerability of Mounjaro were generally consistent with its established profile. The most commonly reported adverse events in SURPASS-CVOT for Mounjaro were gastrointestinal-related, generally mild-to-moderate in severity, and occurred primarily during the dose-escalation period. Please see **Indications and Safety Summary with Warnings** below and full [** _Prescribing Information_**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4759529-1&h=976266758&u=https%3A%2F%2Fuspl.lilly.com%2Fmounjaro%2Fmounjaro.html%3Fs%3Dpi&a=Prescribing+Information) and [** _Medication Guide_**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4759529-1&h=2224540135&u=https%3A%2F%2Fuspl.lilly.com%2Fmounjaro%2Fmounjaro.html%3Fs%3Dmg&a=Medication+Guide). For more information about Mounjaro, please visit [**www.Mounjaro.lilly.com**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4759529-1&h=4206604422&u=https%3A%2F%2Fwww.mounjaro.lilly.com%2F&a=www.Mounjaro.lilly.com). ##### *Inclusion in Pharma Fridays does not suggest an endorsement by Endocrine News or the Endocrine Society. * * * ## TOPICS IN THIS ARTICLE: [Pharma Fridays](https://endocrinenews.endocrine.org/category/pharma-fridays/) ←[Experts to Debut Society’s Center on Obesity and New Scientific Statement ](https://endocrinenews.endocrine.org/experts-to-debut-societys-center-on-obesity-and-new-scientific-statement/) ## RELATED ARTICLES * ### [ Eureka! The Top Endocrine Discoveries of 2024 – Part V ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-discoveries-of-2024-part-v/) December 30, 2024 * ### [ Eureka! The Top Endocrine Science of 2024 – Part IV ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-science-of-2024-part-iv/) December 26, 2024 * ### [ Eureka! The Top Endocrine Science of 2024 – Part III ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-science-of-2024-part-iii/) December 23, 2024 * * * ADVERTISEMENT ![August 2026](https://endocrinenews.endocrine.org/wp-content/uploads/08.26_coverPROOF001-749x1024.jpg) [View Archives](https://endocrinenews.endocrine.org/magazine-issues/) ADVERTISEMENT ADVERTISEMENT ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/scientists_optim-1024x569.jpg) ## Join the Global Movement Advancing Endocrine Science and Medicine Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities. [Join Today](https://www.endocrine.org/membership) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_Society_Logo.webp)](https://www.endocrine.org/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) [![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/facebook.svg)](http://www.facebook.com/pages/The-Endocrine-Society/93758955863)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/x.svg)](https://x.com/TheEndoSociety)[![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/linkedin.svg)](https://www.linkedin.com/company/the-endocrine-society/) ## Research * * * ### Health Topics [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) [Transgender Health](https://endocrinenews.endocrine.org/category/health-topic/transgender-health/) ### Patient Populations [](https://endocrinenews.endocrine.org/category/health-topic/adrenal/)[Health Disparities](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/)
## Related Clinical Research

- [Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes](https://medichelpline.com/clinical-feed/endocrine-news-33-compare-and-contrast-as-glucagon-like-peptide-1-receptor-agonist-access-expands-comparative-heart-outcomes-matter.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [GLP‑1 and Dual GIP/GLP‑1 Receptor Agonists: Psychopharmacology and Potential Neuropsychiatric Effe](https://medichelpline.com/clinical-feed/pubmed-42624955.md) (DOI: 10.1007/s11920-026-01709-w)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.